{"id":31649,"date":"2017-08-11T09:46:13","date_gmt":"2017-08-11T08:46:13","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=31649"},"modified":"2017-08-11T09:46:13","modified_gmt":"2017-08-11T08:46:13","slug":"actualitzacio-terapeutica-en-lesclerosi-multiple","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/","title":{"rendered":"Actualizaci\u00f3n terap\u00e9utica en la esclerosis m\u00faltiple"},"content":{"rendered":"<figure id=\"attachment_31650\" aria-describedby=\"caption-attachment-31650\" style=\"width: 372px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/07\/esclerosi-multiple-maig-2017-1.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-31650\" alt=\"esclerosi-multiple-maig-2017 (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/07\/esclerosi-multiple-maig-2017-1-1024x603.jpg\" width=\"372\" height=\"219\" \/><\/a><figcaption id=\"caption-attachment-31650\" class=\"wp-caption-text\">Asistentes a la sesi\u00f3n informativa<\/figcaption><\/figure>\n<p><b>La esclerosis m\u00faltiple (EM) es una enfermedad neurodegenerativa y cr\u00f3nica del sistema nervioso<\/b> <b>central <\/b>que suele afectar a personas de entre 20 y 40 a\u00f1os. Los s\u00edntomas suelen presentarse en brotes, que pueden dejar secuelas y discapacidad. Tambi\u00e9n pueden presentarse de forma progresiva. La supervivencia es de unos treinta a\u00f1os, puesto que menos del 10% de las personas afectadas mueren como consecuencia directa de la esclerosis m\u00faltiple. A menudo, esta supervivencia es con discapacidad, sobre todo en los casos m\u00e1s graves.<\/p>\n<p>Seg\u00fan los datos epidemiol\u00f3gicos, <b>en Catalu\u00f1a la prevalencia de esta enfermedad se sit\u00faa entre 40-60 personas por 100.000 habitantes, aunque un reciente estudio incrementa esta cifra hasta 91 personas por 100.000 habitantes<\/b>. Afecta cerca del doble de mujeres que de hombres (fuente y m\u00e1s informaci\u00f3n: <a href=\"http:\/\/canalsalut.gencat.cat\/ca\/detalls\/article\/Esclerosi_multiple\">Canal Salud de la Generalitat<\/a>).<\/p>\n<p>El 25 de mayo el COFB y la <a href=\"http:\/\/www.scfarmclin.org\/\">Sociedad Catalana de Farmacia Cl\u00ednica<\/a> (SCFC) organizaron una <strong>sesi\u00f3n informativa sobre la actualizaci\u00f3n terap\u00e9utica en la esclerosis m\u00faltiple<\/strong>.<\/p>\n<p><strong>Julio Martinez<\/strong>, presidente de la SCFC, present\u00f3 el acto en el que se trataron diversos temas de inter\u00e9s:<\/p>\n<ul>\n<li>Actualizaci\u00f3n terap\u00e9utica de la esclerosis m\u00faltiple: pasado, presente y futuro, a cargo de la Dra. <b>Yolanda Blanco<\/b>, neur\u00f3loga adjunta del Hospital Cl\u00ednic de Barcelona<\/li>\n<li>Papel de la farmacia hospitalaria en el manejo del paciente con esclerosis m\u00faltiple, a cargo de la Dra. <b>N\u00faria Pola<\/b>, farmac\u00e9utica adjunta del Hospital de Granollers.<\/li>\n<li>Actualizaci\u00f3n de datos farmacoecon\u00f3micos en esclerosis m\u00faltiple, a cargo del dr. <b>Pedro Ventayol<\/b>, farmac\u00e9utico jefe de secci\u00f3n del Hospital Universitario de Son Espases de Palma de Mallorca.<\/li>\n<\/ul>\n<p><b>Otras actividades publicadas en el Blog en las que tambi\u00e9n ha participado el SCFC:<\/b><\/p>\n<ul>\n<li><a href=\"http:\/\/blog.cofb.cat\/atencio-farmaceutica-en-nutricio-artificial-2\/\">Atenci\u00f3n farmac\u00e9utica en nutrici\u00f3n artificial<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/la-figura-del-farmaceutic-necessaria-en-la-ruta-assistencial-de-la-insuficiencia-cardiaca-la-fibril%C2%B7lacio-auricular\/\">La figura del farmac\u00e9utico, necesaria en la ruta asistencial de la insuficiencia card\u00edaca y la fibrilaci\u00f3n auricular<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/actualitzacio-en-vih\/\">Actualizaci\u00f3n en VIH<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/insulinitzacio-posada-al-dia\/\">Insulinizaci\u00f3n: puesta al d\u00eda<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/farmacoeconomia-per-principiants\/\">Farmacoeconom\u00eda para principiantes<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/curs-sobre-anticoagulants-orals-daccio-directa-en-fibril%C2%B7lacio-auricular-no-valvular\/\">Curso sobre anticoagulantes orales de acci\u00f3n directa en fibrilaci\u00f3n auricular no valvular<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/taller-dintroduccio-lanalisi-estadistica\/\">Taller de introducci\u00f3n al an\u00e1lisis estad\u00edstico<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/taller-de-lectura-critica-de-metanalisi-de-comparacions-indirectes-i-metanalisi-en-xarxa\/\">Taller de lectura cr\u00edtica de metan\u00e1lisis de comparaciones indirectas y metan\u00e1lisis en red<\/a><\/li>\n<\/ul>\n<figure id=\"attachment_31652\" aria-describedby=\"caption-attachment-31652\" style=\"width: 477px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/07\/esclerosi-multiple-maig-2017-3.jpg\"><img decoding=\"async\" class=\"wp-image-31652\" alt=\"esclerosi-multiple-maig-2017 (3)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/07\/esclerosi-multiple-maig-2017-3-1024x683.jpg\" width=\"477\" height=\"318\" \/><\/a><figcaption id=\"caption-attachment-31652\" class=\"wp-caption-text\">Los docentes de la sesi\u00f3n, de izquierda a derecha: Yolanda Blanco (Hospital Cl\u00ednic), Pere Ventanyol (Hospital Universitario Son Espases), Julio Mart\u00ednez (presidente SCFC) y N\u00faria Pola (Hospital de Granollers)<\/figcaption><\/figure>\n<p align=\"right\"><b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Con la colaboraci\u00f3n de:<\/b><\/p>\n<p align=\"right\"><b><a href=\"https:\/\/www.sanofigenzyme.com\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\"wp-image-31654 alignright\" alt=\"logo sanofi-genzyme\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/07\/logo-sanofi-genzyme.jpg\" width=\"211\" height=\"54\" \/><\/a>\u00a0 <\/b><\/p>\n<p align=\"right\">","protected":false},"excerpt":{"rendered":"<p>La esclerosis m\u00faltiple (EM) es una enfermedad neurodegenerativa y cr\u00f3nica del sistema nervioso central que suele afectar a personas de entre 20 y 40 a\u00f1os. Los s\u00edntomas suelen presentarse en brotes, que pueden dejar secuelas y discapacidad. Tambi\u00e9n pueden presentarse de forma progresiva. La supervivencia es de unos treinta a\u00f1os, puesto que [\u2026]<\/p>","protected":false},"author":1,"featured_media":31650,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[2221,215,480,70,286],"class_list":["post-31649","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-em","tag-esclerosi-multiple","tag-farmacia-hospitalaria","tag-formacio","tag-societat-catalana-de-farmacia-clinica"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Actualitzaci\u00f3 terap\u00e8utica en l&#039;esclerosi m\u00faltiple<\/title>\n<meta name=\"description\" content=\"Actualitzaci\u00f3 terap\u00e8utica en l&#039;esclerosi m\u00faltiple. Societat Catalana de Farm\u00e0cia Cl\u00ednica\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actualitzaci\u00f3 terap\u00e8utica en l&#039;esclerosi m\u00faltiple\" \/>\n<meta property=\"og:description\" content=\"Actualitzaci\u00f3 terap\u00e8utica en l&#039;esclerosi m\u00faltiple. Societat Catalana de Farm\u00e0cia Cl\u00ednica\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-11T08:46:13+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Actualitzaci\u00f3 terap\u00e8utica en l&#8217;esclerosi m\u00faltiple\",\"datePublished\":\"2017-08-11T08:46:13+00:00\",\"dateModified\":\"2017-08-11T08:46:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"EM\",\"esclerosi m\u00faltiple\",\"farm\u00e0cia hospital\u00e0ria\",\"Formaci\u00f3\",\"Societat Catalana de Farm\u00e0cia Cl\u00ednica\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/\",\"name\":\"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2017-08-11T08:46:13+00:00\",\"dateModified\":\"2017-08-11T08:46:13+00:00\",\"description\":\"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple. Societat Catalana de Farm\u00e0cia Cl\u00ednica\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualitzaci\u00f3 terap\u00e8utica en l&#8217;esclerosi m\u00faltiple\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple","description":"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple. Societat Catalana de Farm\u00e0cia Cl\u00ednica","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/","og_locale":"es_ES","og_type":"article","og_title":"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple","og_description":"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple. Societat Catalana de Farm\u00e0cia Cl\u00ednica","og_url":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2017-08-11T08:46:13+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Actualitzaci\u00f3 terap\u00e8utica en l&#8217;esclerosi m\u00faltiple","datePublished":"2017-08-11T08:46:13+00:00","dateModified":"2017-08-11T08:46:13+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage"},"thumbnailUrl":"","keywords":["EM","esclerosi m\u00faltiple","farm\u00e0cia hospital\u00e0ria","Formaci\u00f3","Societat Catalana de Farm\u00e0cia Cl\u00ednica"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/","url":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/","name":"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage"},"thumbnailUrl":"","datePublished":"2017-08-11T08:46:13+00:00","dateModified":"2017-08-11T08:46:13+00:00","description":"Actualitzaci\u00f3 terap\u00e8utica en l'esclerosi m\u00faltiple. Societat Catalana de Farm\u00e0cia Cl\u00ednica","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2017\/08\/11\/actualitzacio-terapeutica-en-lesclerosi-multiple\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Actualitzaci\u00f3 terap\u00e8utica en l&#8217;esclerosi m\u00faltiple"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"L\u2019esclerosi m\u00faltiple (EM) \u00e9s una malaltia neurodegenerativa i cr\u00f2nica del sistema nervi\u00f3s central que sol afectar persones d\u2019entre 20 i 40 anys. Els s\u00edmptomes acostumen a presentar-se en brots, que poden deixar seq\u00fceles i discapacitat. Tamb\u00e9 es poden presentar de forma progressiva. La superviv\u00e8ncia \u00e9s d\u2019uns trenta anys, ja que [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/31649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=31649"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/31649\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=31649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=31649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=31649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}